Drug Type Small molecule drug |
Synonyms Levocetirizine/montelukast, Montelukast/levocetirizine + [2] |
Target |
Mechanism CysLT1 antagonists(Cysteinyl leukotriene receptor 1 antagonists), H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC35H36ClNNaO3S |
InChIKeyZMFQNQCXWQXCFO-HKHDRNBDSA-N |
CAS Registry151767-02-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rhinitis, Allergic, Perennial | Phase 2 | KR | 23 Oct 2018 | |
allergic rhinitis with asthma | Phase 2 | KR | 01 Sep 2014 |
NCT02552667 (Pubmed) Manual | Phase 3 | 228 | (vksizlmhlv) = vnoiymkted qeszolotxu (djwrubicjg, 0.06) | Superior | 01 Jul 2018 | ||
montelukast | (vksizlmhlv) = xoantgvdqr qeszolotxu (djwrubicjg, 0.06) |